Benzinga | Nov 12, 2020 07:07AM EST

Galmed Pharmaceuticals Q3 EPS $(0.32) Misses $(0.30) Estimate

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.30) by 6.67 percent. This is a 52.38 percent decrease over losses of $(0.21) per share from the same period last year.